CYCN · Cyclerion Therapeutics Inc

-

Please sign in to comment on CYCN

1 Comment

Admin

4 years, 1 month ago

Cyclerion Therapeutics, Inc is currently in a long term uptrend where the price is trading 7.5% above its 200 day moving average.

From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.2.

Cyclerion Therapeutics, Inc's total revenue sank by 91.0% to $133K since the same quarter in the previous year.

Its net income has increased by 99.9% to $-19K since the same quarter in the previous year.

Finally, its free cash flow grew by 37.0% to $-14M since the same quarter in the previous year.

Based on the above factors, Cyclerion Therapeutics, Inc gets an overall score of 4/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US23255M1053
Sector	Healthcare
Industry	Biotechnology

Beta	1.67
Market Cap	10M
PE Ratio	None
Target Price	4
Dividend Yield	None

ABOUT

Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN · Cyclerion Therapeutics Inc

-

Cyclerion Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cyclerion Therapeutics Inc using a moving average strategy